de Moraes Luciana V, Bueno Valquiria, Marguti Ivo, Martins Gislâine A, Vallochi Adriana L, Yamamoto Guilherme L, Panajotopoulos Nicolas, Mengel José O, Rizzo Luiz V
Laboratory of Clinical Immunology, Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, SP, Brazil.
Transpl Immunol. 2008 Feb;18(4):330-7. doi: 10.1016/j.trim.2007.09.001. Epub 2007 Oct 11.
Spleen or spleen plus bone marrow cells from (BALB/cxC57Bl/6)F1 donors were transferred into BALB/c recipients 21 days before skin or cardiac transplantation. Prolonged graft survival was observed on recipients treated with the mixture of donor-derived cells as compared to those treated with spleen cells alone. We evaluated the expression of CD45RB and CD44 by splenic CD4+ and CD8+ T cells 7 and 21 days after donor cell transfer. The populations of CD8+CD45RBlow and CD8+CD44high cells were significantly decreased in mice pre-treated with donor spleen and bone marrow cells as compared to animals treated with spleen cells only, although these cells expanded in both groups when compared to an earlier time-point. No differences were observed regarding CD4+ T cell population when recipients of donor-derived cells were compared. An enhanced production of IL-10 was observed seven days after transplantation in the supernatants of spleen cell cultures of mice treated with spleen and bone marrow cells. Taken together these data suggest that donor-derived bone marrow cells modulate the sensitization of the recipient by semi-allogeneic spleen cells in part by delaying the generation of activated/memory CD8+ T cells leading to enhanced graft survival.
在皮肤或心脏移植前21天，将（BALB/c×C57Bl/6）F1供体的脾脏或脾脏加骨髓细胞移植到BALB/c受体中。与仅用脾细胞治疗的受体相比，用供体来源细胞混合物治疗的受体观察到移植存活时间延长。我们在供体细胞移植后7天和21天评估了脾脏CD4⁺和CD8⁺T细胞中CD45RB和CD44的表达。与仅用脾细胞治疗的动物相比，用供体脾脏和骨髓细胞预处理的小鼠中CD8⁺CD45RBlow和CD8⁺CD44high细胞群体显著减少，尽管与更早的时间点相比，这两组细胞均有扩增。比较供体来源细胞的受体时，未观察到CD4⁺T细胞群体有差异。在用脾脏和骨髓细胞治疗的小鼠脾细胞培养上清液中，移植后7天观察到IL-10产生增加。综上所述，这些数据表明供体来源的骨髓细胞部分通过延迟活化/记忆性CD8⁺T细胞的产生来调节受体对半同种异体脾细胞的致敏作用，从而提高移植存活率。
